Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
Wimazal, F
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. [electronic resource] - European journal of clinical investigation May 2009 - 406-11 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1365-2362
10.1111/j.1365-2362.2009.02108.x doi
Administration, Oral
Aged
Benzoates--therapeutic use
Deferasirox
Female
Humans
Iron--analysis
Iron Chelating Agents--therapeutic use
Iron Overload--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Treatment Outcome
Triazoles--therapeutic use
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. [electronic resource] - European journal of clinical investigation May 2009 - 406-11 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1365-2362
10.1111/j.1365-2362.2009.02108.x doi
Administration, Oral
Aged
Benzoates--therapeutic use
Deferasirox
Female
Humans
Iron--analysis
Iron Chelating Agents--therapeutic use
Iron Overload--drug therapy
Male
Middle Aged
Myelodysplastic Syndromes--drug therapy
Treatment Outcome
Triazoles--therapeutic use